🇺🇸 CGT9486 in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bilirubin Conjugated Increased — 1 report (16.67%)
  2. Blood Alkaline Phosphatase Increased — 1 report (16.67%)
  3. Blood Bilirubin Increased — 1 report (16.67%)
  4. Erysipelas — 1 report (16.67%)
  5. Escherichia Bacteraemia — 1 report (16.67%)
  6. Liver Function Test Increased — 1 report (16.67%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is CGT9486 approved in United States?

CGT9486 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for CGT9486 in United States?

Cogent Biosciences, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.